
Sign up to save your podcasts
Or
Matthew During, author of a phase I study of gene therapy in the treatment of Parkinson's disease dicusses the study, designed to assess safety and tolerability, shows encouraging early results for the treatment of Parkinson's disease and other neurodegenerative disorders.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Matthew During, author of a phase I study of gene therapy in the treatment of Parkinson's disease dicusses the study, designed to assess safety and tolerability, shows encouraging early results for the treatment of Parkinson's disease and other neurodegenerative disorders.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
132 Listeners
811 Listeners
131 Listeners
325 Listeners
493 Listeners
3,332 Listeners
111,864 Listeners
90 Listeners
1,095 Listeners
185 Listeners
349 Listeners
23 Listeners
0 Listeners
0 Listeners
2 Listeners
1 Listeners
0 Listeners
2 Listeners
0 Listeners
15,237 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners
0 Listeners
26,527 Listeners
0 Listeners
0 Listeners
0 Listeners